- Home
- ELAB vs CDT Comparison
ELAB vs CDT Comparison
Compare ELAB & CDT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ELAB | CDT |
|---|---|---|
| Founded | 2020 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.2M | 3.4M |
| IPO Year | 2023 | N/A |
Fundamental Metrics
Financial Performance| Metric | ELAB | CDT |
|---|---|---|
| Price | $5.12 | $1.69 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 30.5K | ★ 284.8K |
| Earning Date | 11-14-2025 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $285,948.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.29 | $1.48 |
| 52 Week High | $99.72 | $2,198.40 |
Technical Indicators
Market Signals| Indicator | ELAB | CDT |
|---|---|---|
| Relative Strength Index (RSI) | 44.67 | 40.24 |
| Support Level | $5.01 | $1.61 |
| Resistance Level | $5.41 | $2.26 |
| Average True Range (ATR) | 0.36 | 0.20 |
| MACD | 0.03 | -0.06 |
| Stochastic Oscillator | 42.18 | 22.34 |
Price Performance
Historical ComparisonAbout ELAB Elevai Labs Inc.
PMGC Holdings Inc advancing in Medical Aesthetics and Biopharmaceutical Innovation. It specializes in Skin Aesthetics, Obesity, and Metabolic Health business.
About CDT Conduit Pharmaceuticals Inc.
CDT Equity Inc, formerly Conduit Pharmaceuticals Inc is a clinical-stage specialty biopharmaceutical company that was formed to facilitate the development and commercialization of clinical assets that have not been or are not being prioritized by biopharmaceutical companies to develop pharmaceutical products that meet the unmet medical needs of patients. The Company's current development pipeline includes a glucokinase activator, which is Phase II ready for autoimmune diseases including uveitis, Hashimoto's Thyroiditis, preterm labor, and renal transplant rejection. The Company's development pipeline also includes a potent, irreversible inhibitor of human Myeloperoxidase (MPO) that has the potential to treat idiopathic male infertility.